Patents by Inventor Dmitry Gabrilovich

Dmitry Gabrilovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200017561
    Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
    Type: Application
    Filed: August 23, 2019
    Publication date: January 16, 2020
    Inventors: FREDERICK L. LOCKE, DARIO ALTIERI, SCOTT ANTONIA, CLAUDIO ANASETTI, DMITRY GABRILOVICH
  • Patent number: 10414810
    Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
    Type: Grant
    Filed: May 7, 2016
    Date of Patent: September 17, 2019
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
  • Patent number: 10314836
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: June 11, 2019
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Publication number: 20180228794
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: April 6, 2018
    Publication date: August 16, 2018
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • Publication number: 20180118798
    Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
    Type: Application
    Filed: May 7, 2016
    Publication date: May 3, 2018
    Inventors: FREDERICK L. LOCKE, DARIO ALTIERI, SCOTT ANTONIA, CLAUDIO ANASETTI, DMITRY GABRILOVICH
  • Patent number: 9956212
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Publication number: 20170273967
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 28, 2017
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • Publication number: 20070003550
    Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
    Type: Application
    Filed: May 12, 2006
    Publication date: January 4, 2007
    Applicant: Introgen Therapeutics, Inc.
    Inventors: Scott Antonia, Dmitry Gabrilovich, Sunil Chada, Kerstin Menander
  • Publication number: 20060063697
    Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increaed or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells.
    Type: Application
    Filed: November 8, 2005
    Publication date: March 23, 2006
    Inventors: Dmitry Gabrilovich, David Carbone, Sunil Chada, Abner Mhashilkar
  • Publication number: 20050171045
    Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increaed or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells.
    Type: Application
    Filed: December 29, 2004
    Publication date: August 4, 2005
    Inventors: Dmitry Gabrilovich, David Carbone, Sunil Chada, Abner Mhashilkar
  • Publication number: 20030045499
    Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increased or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells.
    Type: Application
    Filed: August 9, 2002
    Publication date: March 6, 2003
    Applicant: Vanderbilt University and Introgen Therapeutics, Inc.
    Inventors: Dmitry Gabrilovich, David Carbone, Sunil Chada, Abner Mhashilkar